DOA
NTLA icon

D'Orazio & Associates’s Intellia Therapeutics NTLA Stock Holding History

D'Orazio & Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-115
Closed -$3K – 288
2018
Q2 		$3K Hold
115
– – ﹤0.01% 241
2018
Q1 		$2K Hold
115
– – ﹤0.01% 260
2017
Q4 		$2K Buy
+115
New +$2.65K ﹤0.01% 299

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

D'Orazio & Associates's NTLA Position: Q3 2018 in Review

D'Orazio & Associates sold out of Intellia Therapeutics (NTLA) in Q3 2018, closing a stake of 115 shares — an estimated $3K sold.

D'Orazio & Associates first reported a position in NTLA in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 157 funds tracked by Wall St. Rank hold NTLA as of Q3 2018.

  • D'Orazio & Associates reported no remaining Intellia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • D'Orazio & Associates sold 115 Intellia Therapeutics shares in Q3 2018, an estimated $3K.
  • D'Orazio & Associates first reported a position in Intellia Therapeutics in Q4 2017 and held it in 3 quarters.
  • D'Orazio & Associates's Intellia Therapeutics position peaked at $3K in Q2 2018.
  • 157 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2018.

Based on D'Orazio & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.